March 1, 2017 – Results from a new prospective clinical trial indicate that high-dose-rate (HDR) brachytherapy administered in a single, 19 Gray (Gy) treatment may be a safe and effective alternative to longer courses of HDR treatment for men with localized prostate cancer. ...continue reading "Single High Dose of Brachytherapy Radiation May Be Safe and Effective for Localized Prostate Cancer"
A small randomized Phase II study for men with progressive castrate-resistant prostate cancer has tested the effects of taking one-fourth the standard dose of Zytiga (abiraterone acetate) after a low-fat breakfast instead of standard dose on an empty stomach.
Taking one-fourth the standard dose with a low-fat breakfast, the study found, can be as effective – and four times less expensive – as taking the standard dose as recommended: on an empty stomach. The finding has significant financial implications.
Abiraterone acetate is a standard treatment for metastatic CRPC. Retail cost is about $8000 per month.
A group of doctors led by Russell Szmulewitz, MD, assistant professor of medicine at the University of Chicago and a specialist in medical treatment of patients with advanced prostate cancer, observed that "despite a large food effect (about a 17-fold increase in CMax with a high-fat meal), abiraterone acetate was administered under fasting conditions in its pivotal trials." ...continue reading "Low-dose Zytiga (abiraterone acetate) with a low-fat breakfast as effective as full dose on an empty stomach, study finds"
A normal prostate wedges neatly into the crowded multifunctional area of a man's lower pelvis.
The prostate in men, like the breast in a woman, is a gland that produces and secretes fluid and controls the fluid's flow.